Agonists of luteinizing hormone-releasing hormone in prostate cancer

Author： Rick Ferenc G   Block Norman L   Schally Andrew V  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.14, Iss.16, 2013-11, pp. : 2237-2247

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Luteinizing hormone-releasing hormone receptor targeted agents for prostate cancer

By Liu Stephen V   Liu Shanshan   Pinski Jacek  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 6, 2011-06 ,pp. : 769-778

Informa Healthcare

Access to resources Recommend Favorite

Luteinising hormone-releasing hormone antagonists in prostate cancer therapy

By Msaouel Pavlos   Diamanti Evanthia   Tzanela Marinela   Koutsilieris Michael  

Expert Opinion on Emerging Drugs, Vol. 12, Iss. 2, 2007-05 ,pp. : 285-299

Informa Healthcare

Access to resources Recommend Favorite

Adjuvant Luteinising Hormone-Releasing Hormone (LHRH)--Agonist Therapy in Prostate Cancer

By Kaisary A.V.   Jarmulowicz M.  

UroOncology, Vol. 3, Iss. 2, 2003-06 ,pp. : 51-62

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Gonadotropin-releasing hormone agonists in breast cancer

By  

Inpharma, Vol. 1, Iss. 1589, 2007-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Gonadotropin-Releasing Hormone Agonists and the Risks of Type 2 Diabetes and Cardiovascular Disease in Men with Prostate Cancer

By Saylor Philip J.  

Drugs, Vol. 71, Iss. 3, 2011-02 ,pp. : 255-261

Adis International

Access to resources Recommend Favorite